目的:2016年实施国家药品价格谈判并不断更新临床指南后,我国肺癌患者抗肿瘤药物的使用情况是否发生变化,目前尚不清楚。这项研究旨在评估抗肿瘤药物的使用趋势,中国主要城市肺癌患者的费用和处方模式。
方法:我们使用2016年1月至2020年12月的数据进行了回顾性观察研究。
方法:本研究使用了来自中国9个主要城市的97家医院的住院和门诊医院数据的处方记录。
方法:回顾性收集研究期间医院处方分析合作项目中肺癌患者的抗肿瘤药物处方共218325张。
方法:抗肿瘤药物使用趋势,肺癌患者的费用和处方模式。
结果:每年的抗肿瘤处方增加了85.6%,从2016年的28594张增加到2020年的53063张(Z=1.71,p=0.086)。蛋白激酶抑制剂(PKI)和单克隆抗体(mAb)的处方显着增加,而在抗代谢物中观察到显著减少,植物生物碱和铂化合物。年度成本从2016年的1.136亿日元逐步增加到2020年的2.783亿日元,增长了145.0%(Z=2.20,p=0.027)。就总成本而言,前三个抗癌药物类别是PKI,抗代谢物和单克隆抗体。在肺癌抗肿瘤药的处方模式中,单一疗法,和三联或更多的药物组合逐渐增加,而双重组合从30.8%显著下降到19.6%。
结论:在研究期间,中国肺癌患者的处方实践发生了重大变化。观察到的趋势可以帮助了解中国肺癌患者的当前药物使用状况,并为未来的药物管理提供信息。
It is unclear whether the use of antineoplastic drugs for patients with lung cancer in China has changed after the implementation of the national drug price negotiation in 2016 and continual update of clinical guidelines. This
study aims to evaluate the trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in major cities of China.
We conducted a retrospective observational
study using data from January 2016 to December 2020.
This
study used prescription records based on inpatient and outpatient hospital data from 97 hospitals in 9 major cities of China.
A total of 218 325 antineoplastic drug prescriptions in patients with lung cancer were retrospectively collected from the Hospital Prescription Analysis Cooperative Project during the study period.
Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer.
The yearly antineoplastic prescriptions increased by 85.6% from 28 594 in 2016 to 53 063 in 2020 (Z=1.71, p=0.086). Significant increases were seen in the prescriptions for protein kinase inhibitors (PKIs) and monoclonal antibodies (mAbs), whereas significant decreases were observed in
antimetabolites, plant alkaloids and platinum compounds. The yearly cost increased progressively by 145.0% from ¥113.6 million in 2016 to ¥278.3 million in 2020 (Z=2.20, p=0.027). The top three anticancer drug classes in terms of total cost were PKIs,
antimetabolites and mAbs. In prescribing patterns of antineoplastic agents for lung cancer, monotherapy, and triple or more drug combinations gradually increased, while dual combinations decreased significantly from 30.8% to 19.6%.
Prescription practices among patients with lung cancer in China underwent major changes during the study period. The observed trends can aid in understanding the present medication use status of patients with lung cancer in China and provide information for future drug management.